explore -WSS

explore

author：entertainment 2025-09-30 18:17:18 - browse：8

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： The unintended consequences of overturning Roe v. Wade

focus

WSS

Information blocking fines are now fair game in health care

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

Why the drug industry's warnings on the IRA's impact fall short

Patients, doctors press FTC to beef up hospital merger scrutiny

Chamber of Commerce, DOJ clash in court over drug prices

Biden declares emergency in flood

focus

explore

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

Judge agrees to delay next hearing in Trump classified documents case

Jerome Adams on the need for new antivirals for Covid

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

Wildfire smoke exposes gaps in outdoor worker protections

White House Covid adviser calls on docs to combat misinformation

Apple is now the first public company to be valued at $3 trillion

House panel takes first step toward fixing drug shortages

Hollywood unions extend contract negotiations for actors

Covid’s new normal has set in amid another rise in cases

focus

FDA panel to weigh safety of artificial wombs for preterm births

Chamber of Commerce, DOJ clash in court over drug prices

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

White House announces new plan to address the growing threat of xylazine in overdose crisis

Akili changes sales model for its ADHD video game treatment

Fed up with FDA, ALS advocates consider a take

focus

hotspot

focus

entertainment